Pfizer’s Wyeth sues Novartis’ Sandoz over breast cancer drug patent
16-11-2021
Delhi court approves Natco generic of Novartis cancer drug
29-08-2019
Pavel Kapysh / Shutterstock.com
Public biopharmaceutical company NextCure has been accused of misappropriating trade secrets in order to create a direct competitor to a biotech’s cancer immunotherapy technology.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
NextCure, Eli Lilly, Immunaccel, cancer treatment, immunotherapy
